Evolution of clinical trials in head and neck cancer

Medicine and Dentistry

• Patient 100%
• Clinical Trial 100%
• Evolution 100%
• Head and Neck Cancer 100%
• Therapeutic Procedure 66%
• Chemoradiotherapy 66%
• Toxicity 33%
• Quality of Life 33%
• Cisplatin 33%
• Recurrent Disease 33%
• Functional Assessment 33%
• Monoclonal Antibody 33%
• Intensity Modulated Radiation Therapy 33%
• Biological Therapy 33%
• Cetuximab 33%
• Induction Chemotherapy 33%
• Head and Neck Tumor 33%
• Organ 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Head and Neck Cancer 100%
• Chemotherapy 66%
• Chemoradiation Therapy 66%
• Toxicity 33%
• Biological Product 33%
• Recurrent Disease 33%
• Cisplatin 33%
• Cetuximab 33%
• Monoclonal Antibody 33%
• Taxane 33%
• Head and Neck Tumor 33%
• Nasopharynx Cancer 33%